Dissertation > Medicine, health > Oncology > Genitourinary tumors > Breast tumor

Detection of CK19mRNA, SBEMmRNA and PIPmRNA in Peripheral Blood of Patients with Breast Cancer and Their Clinical Significance

Author LinHaoYu
Tutor SunShuMing
School Shantou University
Course General Surgery
Keywords Breast tumor Reverse transcription - polymerase chain reaction Peripheral blood Keratin 19 mRNA Mammary mucin mRNA Prolactin -induced protein mRNA
CLC R737.9
Type Master's thesis
Year 2009
Downloads 35
Quotes 0
Download Dissertation

Background and Purpose: Breast cancer is one of the most common malignancy in women in developed countries, and its incidence in the first female malignancy and mortality after lung, ranking No. 2. In recent years, for malignant tumors in the sub-clinical phase of the cycle the detection of micrometastases increasingly the attention of scholars at home and abroad, and peripheral blood micrometastasis detection and concern for its simple and non-invasive, convenient follow-up. However, it has yet to find a single micrometastasis marker on the specificity and sensitivity of the results are satisfactory. Reported in the literature combined detection of multiple markers can effectively improve the detection rate of micrometastases, but indicators of joint detection is still a lack of unified standards. In this study, the use of RT-PCR by the combined detection of breast cancer in the peripheral blood of patients CK19mRNA SBEMmRNA PIPmRNA explore the feasibility of the three as markers of micrometastasis in peripheral blood, as well as the combined detection of three to improve the detection rate of micrometastases . Methods: 50 patients with breast cancer was detected by RT-PCR, 20 patients with colorectal cancer, 21 cases of benign breast patients in the peripheral blood of 20 healthy volunteers CK19mRNA SBEMmRNA PIPmRNA. Analysis with breast cancer and the relationship with clinical and pathological features and the combined detection of single indicators positive rate difference. Results: (1) in the peripheral blood of 20 healthy volunteers and 21 patients with benign breast patients were not found positive expression of CK19mRNA, SBEMmRNA or PIPmRNA are. 4 cases (20.0%) of the 20 cases of patients with colorectal specimens found CK19mRNA positive. Detected in 50 patients with breast cancer specimens CK19mRNA positive in 18 cases (36.0%), the group with the healthy volunteers and patients with benign breast group differences significant sex (P lt; 0, 01), and in patients with colorectal group There was no significant difference (P gt; 0, 05); detected SBEMmRNA positive in 14 cases (28.0%), PIPmRNA positive in 9 patients (18.0%), with the group of patients with colorectal, a group of patients with benign breast disease and healthy volunteers group comparison showed a significant difference (P lt; 0 05). (2) the positive CK19mRNA SBEMmRNA or PIPmRNA rate with age, menstruation, pathological type, degree of differentiation, size, ER, PR, C-erbB-2, compared There was no significant difference (P gt; 0.05). The CK19mRNA, SBEMmRNA positive rate with clinical stage III stage IV positive rates were 69.2% and 61.5% compared with phase I (20.0%, 20.0%) II period (25.0%, 15.6%), the difference statistics significance (P lt; 0.05); positive rate PIPmRNA difference was not statistically significant. (3) SBEMmRNA, PIPmRNA, and CK19mRNA positive rate consistency test Kappa values ??were 0.165, -0.095, -0.032 (P gt; 0.05), can be considered a pairwise comparison of the consistency of the poor; joint detection were positive rate increased by 18.0%, 36.0%, 28.0% to 38% (19/50), 56% (24/50), 48% (28/50), with a single indicator of comparison, the difference there is significant significance (P lt; 0.01) United three genes, can be positive rate increased to 62% (31/50), with either a single indicator or any two indexes, the differences were significant significance (P lt; 0.01). Conclusion: (1) Small Breast Epithelial Mucin mRNA PIP mRNA in peripheral blood of breast cancer micrometastases markers with high specificity can be independent as a marker of breast cancer micrometastases, while CK19mRNA can be used as markers of tumors of epithelial origin, but as micrometastases of breast cancer markers, its specificity is yet to be further explored. (2) CK19mRNA, SBEM mRNA expression in breast cancer patients with clinical stage III IV patients positive rate compared to the Phase I and II patients; while PIPmRNA positive rate difference was not statistically significant. (3) The positive rate SBEMmRNA PIPmRNA and CK19mRNA age, menstruation, histological type, degree of differentiation, size, ER, PR, C-erbB-2 and other clinical indicators showed no significant correlation. (4) SBEMmRNA, PIPmRNA, and CK19mRNA positive rate of pairwise comparisons of consistency is poor. (5) joint detection SBEMmRNA, PIPmRNA, and CK19mRNA, the positive rate of 18.0%, 36.0%, 28.0% to 62% (31/50), higher than any single index or any joint detection of two indicators; The joint detection can improve the positive rate of micrometastasis in peripheral blood.

Related Dissertations
More Dissertations